TrialPharmacotherapy2021

NR3C2 genotype is associated with response to spironolactone in diastolic heart failure patients from the Aldo-DHF trial.

Leanne Dumeny et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.